Given the emergence of triple-negative breast cancer as a distinct clinical entity, designers of clinical trial matching systems should include progesterone receptor status in their matching criteria and prompt patients to ask their physicians about it if necessary. This evidence concerns the gene PGR and triple-negative breast carcinoma.